9.24
전일 마감가:
$9.24
열려 있는:
$9.24
하루 거래량:
454.80K
Relative Volume:
0.54
시가총액:
$657.62M
수익:
$133.62M
순이익/손실:
$-177.37M
주가수익비율:
-3.1972
EPS:
-2.89
순현금흐름:
$23.50M
1주 성능:
+3.01%
1개월 성능:
+7.94%
6개월 성능:
-52.98%
1년 성능:
-56.56%
Xencor Inc Stock (XNCR) Company Profile
명칭
Xencor Inc
전화
626-305-5900
주소
465 N. HALSTEAD ST., PASADENA, CA
XNCR을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
XNCR
Xencor Inc
|
9.24 | 657.62M | 133.62M | -177.37M | 23.50M | -2.89 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-04-21 | 개시 | William Blair | Outperform |
2024-12-12 | 개시 | Wells Fargo | Overweight |
2024-12-02 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2024-04-16 | 재확인 | BTIG Research | Buy |
2024-02-28 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2023-05-19 | 개시 | BofA Securities | Buy |
2022-12-06 | 개시 | Cowen | Outperform |
2022-10-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2022-09-21 | 개시 | JP Morgan | Overweight |
2022-07-06 | 재개 | Canaccord Genuity | Buy |
2022-02-11 | 개시 | BMO Capital Markets | Outperform |
2022-01-21 | 개시 | SMBC Nikko | Outperform |
2021-12-15 | 개시 | H.C. Wainwright | Buy |
2021-10-15 | 재개 | BTIG Research | Buy |
2021-02-24 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
2020-03-04 | 개시 | Barclays | Underweight |
2020-02-25 | 업그레이드 | Guggenheim | Neutral → Buy |
2020-01-30 | 개시 | RBC Capital Mkts | Outperform |
2019-11-20 | 재개 | Guggenheim | Neutral |
2019-08-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
2019-08-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
2019-06-13 | 개시 | Mizuho | Buy |
2019-04-12 | 개시 | Guggenheim | Buy |
2019-03-27 | 개시 | Berenberg | Buy |
2019-03-15 | 개시 | Raymond James | Outperform |
2018-09-10 | 재개 | BTIG Research | Buy |
2018-03-28 | 재개 | Leerink Partners | Outperform |
2017-03-02 | 개시 | Instinet | Neutral |
2017-03-02 | 재확인 | Wedbush | Outperform |
2016-10-04 | 개시 | Piper Jaffray | Overweight |
2015-12-22 | 개시 | Canaccord Genuity | Buy |
2015-08-05 | 재확인 | MLV & Co | Buy |
2015-02-12 | 재확인 | Oppenheimer | Outperform |
2015-01-28 | 재확인 | MLV & Co | Buy |
2014-07-11 | 개시 | Oppenheimer | Outperform |
모두보기
Xencor Inc 주식(XNCR)의 최신 뉴스
Bank of New York Mellon Corp Reduces Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Is Xencor Inc. a good long term investmentOver 200% growth - PrintWeekIndia
How Xencor Inc. stock performs during market volatilityDaily Top Gainers - Newser
What drives Xencor Inc. stock priceAccelerated wealth building - Autocar Professional
Xencor Inc. Stock Analysis and ForecastHigh-yield investments - PrintWeekIndia
What analysts say about Xencor Inc. stockUnmatched profit growth - Autocar Professional
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Arizona State Retirement System - Defense World
Why Xencor Inc. stock attracts strong analyst attentionFree Access to Community - Newser
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Teacher Retirement System of Texas - Defense World
Where are the Opportunities in (XNCR) - news.stocktradersdaily.com
What risks could impact Xencor Inc. stock performanceVerified Return Tips - Newser
Xencor’s Phase 2 Study on Vudalimab in Prostate Cancer: Key Update and Market Impact - The Globe and Mail
Principal Financial Group Inc. Grows Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World
[Latest] Global Ultomiris Drug Market Size/Share Worth USD 64.12 Billion by 2034 at a 31.52% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
What makes Xencor Inc. stock price move sharplyLow Volatility High Yield Stocks - Newser
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Fed. Circ. Won't Revisit Jepson Claim Ruling In Xencor IP Case - Law360
(XNCR) Investment Analysis - news.stocktradersdaily.com
Closing Figures Unveiled: Xencor Inc (XNCR) Drop -8.18, Closes at 8.31 - DWinneX
Rhumbline Advisers Has $1.74 Million Stake in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor (NASDAQ:XNCR) Shares Down 5.7% on Insider Selling - Defense World
(XNCR) On The My Stocks Page - news.stocktradersdaily.com
Xencor director Gustafson sells shares worth $27,595 - Investing.com Australia
Xencor director Montgomery sells shares worth $20,422 - Investing.com
Xencor Inc (XNCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):